Redx Pharma Plc's (LON:REDX) Chief Scientific officer Richard Armer joins Proactive London's Katie Pilbeam to recap on its RXC007 programme - a drug which has potential for development in multiple fibrotic conditions.
Armer explains how they aim to treat Idiopathic Pulmonary Fibrosis (IPF) a life threatening lung disease, with a prognostic similar to many cancers.
The firm recently announced that the first subject has been dosed in a Phase 1 study in healthy volunteers.